Results 81 to 90 of about 839,337 (241)
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
New England Journal of Medicine, 2021 Background The messenger RNA (mRNA)–based vaccines BNT162b2 and mRNA-1273 are more than 90% effective against coronavirus disease 2019 (Covid-19). However, their comparative effectiveness for a range of outcomes across diverse populations is unknown ...B. Dickerman, H. Gerlovin, Arin L. Madenci, Katherine E Kurgansky, B. Ferolito, Michael J. Figueroa Muñiz, D. Gagnon, J. Gaziano, Kelly Cho, J. Casas, M. Hernán +10 moresemanticscholar +1 more sourceHybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study. [PDF]
EClinicalMedicineGarrett N, Tapley A, Hudson A, Dadabhai S, Zhang B, Mgodi NM, Andriesen J, Takalani A, Fisher LH, Kee JJ, Magaret CA, Villaran M, Hural J, Andersen-Nissen E, Ferarri G, Miner MD, Le Roux B, Wilkinson E, Lessells R, de Oliveira T, Odhiambo J, Shah P, Polakowski L, Yacovone M, Samandari T, Chirenje Z, Elyanu PJ, Makhema J, Kamuti E, Nuwagaba-Biribonwoha H, Badal-Faesen S, Brumskine W, Coetzer S, Dawson R, Delany-Moretlwe S, Diacon AH, Fry S, Gill KM, Ebrahim Hoosain ZA, Hosseinipour MC, Inambao M, Innes C, Innes S, Kalonji D, Kasaro M, Kassim P, Kayange N, Kilembe W, Laher F, Malahleha M, Maluleke VL, Mboya G, McHarry K, Mitha E, Mngadi K, Mda P, Moloantoa T, Mutuluuza CK, Naicker N, Naicker V, Nana A, Nanvubya A, Nchabeleng M, Otieno W, Potgieter EL, Potloane D, Punt Z, Said J, Singh Y, Tayob MS, Vahed Y, Wabwire DO, McElrath MJ, Kublin JG, Bekker LG, Gilbert PB, Corey L, Gray GE, Huang Y, Kotze P, CoVPN 3008 Ubuntu Study Team. +80 moreeuropepmc +2 more sourcesSudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA-1273:A Danish Population-Based Cohort Study [PDF]
, 2023 Objective: To compare the occurrence of sudden sensorineural hearing loss following immunization with BNT162b2 (Comirnaty®; Pfizer BioNTech) or mRNA-1273 (Spikevax®; Moderna) to the occurrence among unvaccinated individuals.Cleary, Brian, Damkier, Per, Hallas, Jesper, Jensen, Peter B., Ladebo, Louise, Lund, Lars Christian, Schmidt, Jesper H. +6 morecore +1 more sourceImmune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
Science, 2021 Description Antibodies dovetail with protection Immune correlates of protection are clinical end points used to gauge vaccine-induced immunogenicity and protection. Corbett et al.Kizzmekia S. Corbett, M. Nason, B. Flach, M. Gagne, S. O'connell, T. Johnston, Shruti N. Shah, V. Edara, K. Floyd, L. Lai, C. McDanal, J. Francica, Barbara Flynn, Kai Wu, A. Choi, M. Koch, O. Abiona, Anne P. Werner, Juan I. Moliva, Shayne F. Andrew, M. Donaldson, J. Fintzi, Dillon R. Flebbe, Evan Lamb, Amy T. Noe, S. Nurmukhambetova, Samantha J Provost, Anthony Cook, A. Dodson, Andrew Faudree, J. Greenhouse, S. Kar, Laurent Pessaint, Maciel Porto, Katelyn Steingrebe, Daniel Valentin, Serge Zouantcha, Kevin W. Bock, Mahnaz Minai, Bianca M. Nagata, R. van de Wetering, Seyhan Boyoglu-Barnum, K. Leung, W. Shi, E. Yang, Yi Zhang, J. Todd, Lingshu Wang, Gabriela Alvarado, H. Andersen, K. Foulds, D. Edwards, J. Mascola, Ian N. Moore, M. Lewis, A. Carfi, D. Montefiori, M. Suthar, A. McDermott, M. Roederer, N. Sullivan, D. Douek, B. Graham, R. Seder +63 moresemanticscholar +1 more sourceInterim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults
Human Vaccines & Immunotherapeutics, 2023 This interim analysis of an ongoing phase 1 randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein (i.e ...Patrick Yassini, Mark Hutchens, Yamuna D. Paila, Lorraine Schoch, Anne Aunins, Uma Siangphoe, Robert Paris +6 moredoaj +1 more sourceComparing the human milk antibody response after vaccination with four COVID-19 vaccines:A prospective, longitudinal cohort study in the Netherlands [PDF]
, 2022 Background: Vaccination of lactating women against COVID-19 may protect not only themselves but also their breastfed infant through human milk. Therefore, it is important to gain insight into the human milk antibody response after immunization with the ...Bakker, S., Bouhuijs, J.H., Coenen, E.R.M., de Groot, C.J.M., Harinck, J.E., Juncker, H.G., Korosi, A., Mulleners, S.J., Oomen, M., Pajkrt, D., Rood, R.D., Ruhé, E.J.M., van Doesburg, M., van Gils, M.J., van Goudoever, J.B., van Keulen, B.J. +15 morecore +1 more sourcePrevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
New England Journal of Medicine, 2021 BACKGROUND: Information is limited regarding the effectiveness of the two-dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) in preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and ...M. Thompson, J. Burgess, A. Naleway, Harmony L. Tyner, Sarang K. Yoon, J. Meece, Lauren E. W. Olsho, A. Caban-Martinez, A. Fowlkes, K. Lutrick, H. Groom, K. Dunnigan, M. Odean, K. Hegmann, Elisha L Stefanski, Laura J. Edwards, Natasha Schaefer-Solle, L. Grant, K. Ellingson, J. Kuntz, Tnelda Zunie, M. Thiese, L. Ivacic, Meredith G. Wesley, Julie Mayo Lamberte, Xiaoxiao Sun, Michael E. Smith, Andrew L. Phillips, Kimberly D. Groover, Young M. Yoo, J. Gerald, Rachel T. Brown, Meghan K Herring, G. Joseph, S. Beitel, Tyson Morrill, Josephine Mak, Patrick Rivers, Brandon Poe, Brian Lynch, Yingtao Zhou, Jing Zhang, Anna Kelleher, Yan Li, Monica Dickerson, E. Hanson, Kyley Guenther, S. Tong, A. Bateman, E. Reisdorf, J. Barnes, E. Azziz‐Baumgartner, D. Hunt, Melissa L. Arvay, P. Kutty, A. Fry, M. Gaglani +56 moresemanticscholar +1 more sourceRelationship between immune response to SARS-CoV2 vaccines and development of breakthrough infection in solid organ transplant recipients: the CONTRAST cohort [PDF]
, 2023 Background: SARS-CoV-2 vaccination in solid organ transplant (SOT) is associated with poorer antibody response (AbR) compared to non-SOT recipients. However, its impact on the risk of breakthrough infection (BI) should yet be assessed.Bonazzetti, Cecilia, Borgese, Laura, Busutti, Marco, Caroccia, Natascia, Comai, Giorgia, Fanì, Francesca, Fornaro, Giacomo, Gamberini, Chiara, Giannella, Maddalena, Gibertoni, Dino, Lazzarotto, Tiziana, Miani, Beatrice, Morelli, Maria Cristina, Pascale, Renato, Pasquini, Zeno, Potena, Luciano, Rinaldi, Matteo, Salvaterra, Elena, Scudeller, Luigia, Tamé, Mariarosa, Tazza, Beatrice, Viale, Pierluigi +21 morecore +1 more sourceImmune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
medRxiv, 2021 Background: In the Coronavirus Efficacy (COVE) trial, estimated mRNA-1273 vaccine efficacy against coronavirus disease-19 (COVID-19) was 94%. SARS-CoV-2 antibody measurements were assessed as correlates of COVID-19 risk and as correlates of protection ...P. Gilbert, D. Montefiori, A. McDermott, Y. Fong, David C. Benkeser, Wei-zhi Deng, Honghong Zhou, Christopher R. Houchens, Karen A. Martins, L. Jayashankar, F. Castellino, B. Flach, Bob C. Lin, S. O'connell, C. McDanal, Amanda Eaton, M. Sarzotti-Kelsoe, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars van der Laan, N. Hejazi, C. Huynh, Jacqueline M. Miller, Hana M. El Sahly, L. Baden, Mira Baron, Luis I. De La Cruz, C. Gay, S. Kalams, Colleen F. Kelley, M. Kutner, M. Andrasik, J. Kublin, L. Corey, K. Neuzil, Lindsay N. Carpp, R. Pajon, D. Follmann, R. Donis, R. Koup +40 moresemanticscholar +1 more source
